All In Biotech

Drug Trial Radar · NCT05176626

Long-term Effectiveness of the Antiobesity Medication Phentermine

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 870 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

870

Actual

Start

Jun 30, 2022

Primary completion

Sep 30, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Wake Forest University Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Johns Hopkins University; Kaiser Permanente; HealthPartners Institute; The University of Texas Health Science Center, Houston; Biomedical Research Institute of New Mexico; WW International Inc; KVK-Tech, Inc.; National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jan 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to understand the long-term effects of the drug phentermine on weight, blood pressure, other health outcomes, and safety. Phentermine has been approved by the US Food and Drug Administration (FDA) for weight management since 1959, but it has not been approved for long-term use (i.e., treatment lasting more than 12 weeks). This trial is designed to learn about the long-term effects of phentermine for up to 2 years because obesity is a chronic disease and expert guidelines recommend long-term use of anti-obesity medications as one treatment option.

Conditions

  • Obesity
  • Obesity; Drug
  • Lifestyle, Healthy

Interventions

  • Online Lifestyle Behavioral TherapyBehavioral

    Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.

  • Phentermine Hydrochloride 8 MGDrug

    At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in body weight (%)Time frame: Baseline to month 24
  2. Change in Systolic Blood Pressure (mmHg)Time frame: Baseline to month 24

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente Southern California

    Los Angeles, California

  • HealthPartners Institute

    Saint Louis Park, Minnesota

  • Atrium Health Wake Forest Baptist Weight Management Center

    Winston-Salem, North Carolina

  • UT Center for Obesity Medicine and Metabolic Performance

    Bellaire, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.